The Advance Market Commitment Pilot for Pneumococcal Vaccines: Outcomes and Impact Evaluation
This report assesses the extent to which the Advanced Market Commitment (AMC) pilot program has achieved its stated objectives and overarching goal of reducing morbidity and mortality from pneumococcal disease by accelerating the development, availability, and uptake of pneumococcal conjugate vaccines (PCVs). The report concludes that the introduction of PCVs through the AMC pilot accelerated immunization coverage against pneumococcal disease across 53 countries eligible for support from Gavi, the Vaccine Alliance and confirms that manufacturers made decisions to expand capacity to serve Gavi countries’ requirements in response to the AMC and its supply agreements.
Author: The Boston Consulting Group
» Download file (English)
1.95 MB PDF (Located at www.gavi.org)
Resource types: Report